Frank Tufaro - Theriva Biologics Chief Officer
| TOVX Stock | USD 1.28 0.02 1.59% |
Insider
Frank Tufaro is Chief Officer of Theriva Biologics
| Age | 69 |
| Address | 9605 Medical Center Drive, Rockville, MD, United States, 20850 |
| Phone | 301 417 4364 |
| Web | https://therivabio.com |
Theriva Biologics Management Efficiency
The company has return on total asset (ROA) of (0.2498) % which means that it has lost $0.2498 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5906) %, meaning that it created substantial loss on money invested by shareholders. Theriva Biologics' management efficiency ratios could be used to measure how well Theriva Biologics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.65 in 2024. Return On Capital Employed is likely to rise to -0.42 in 2024. At this time, Theriva Biologics' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 29.2 M in 2024, whereas Total Current Assets are likely to drop slightly above 14.4 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Peter Rhode | HCW Biologics | 66 | |
| MD BA | Lumos Pharma | 69 | |
| FACC FAHA | Milestone Pharmaceuticals | 66 | |
| Hing Wong | HCW Biologics | 70 | |
| Guy Rousseau | Milestone Pharmaceuticals | N/A | |
| Richard Hawkins | Lumos Pharma | 75 | |
| Jeff Nelson | Milestone Pharmaceuticals | 43 | |
| Kristin Ainsworth | Seres Therapeutics | N/A | |
| Carl Langren | Lumos Pharma | 69 | |
| Bradley JD | Lumos Pharma | 45 | |
| Philippe MBA | Milestone Pharmaceuticals | 62 | |
| FACC MD | Milestone Pharmaceuticals | 60 | |
| Susan MS | Eliem Therapeutics | N/A | |
| Robert MBA | Eliem Therapeutics | 56 | |
| Kimberly Sheehan | Milestone Pharmaceuticals | N/A | |
| BBA CPA | Lumos Pharma | 57 | |
| Lorenz Muller | Milestone Pharmaceuticals | 60 | |
| Katherine Taudvin | Scpharmaceuticals | N/A | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| Erin Lavelle | Eliem Therapeutics | 47 | |
| Lori CPA | Lumos Pharma | 40 | |
Management Performance
| Return On Equity | -0.59 | ||||
| Return On Asset | -0.25 |
Theriva Biologics Leadership Team
Elected by the shareholders, the Theriva Biologics' board of directors comprises two types of representatives: Theriva Biologics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Theriva. The board's role is to monitor Theriva Biologics' management team and ensure that shareholders' interests are well served. Theriva Biologics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Theriva Biologics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Steven CPA, CFO, CEO | ||
| Vincent Perrone, Director Communication | ||
| Frank Tufaro, Chief Officer | ||
| Vince Wacher, Head Development | ||
| Lara Guzman, Director Operations | ||
| Ramon Alemany, Senior Board | ||
| Michael MD, Senior Development |
Theriva Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Theriva Biologics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.59 | ||||
| Return On Asset | -0.25 | ||||
| Current Valuation | (11.11 M) | ||||
| Shares Outstanding | 2.78 M | ||||
| Shares Owned By Insiders | 10.48 % | ||||
| Shares Owned By Institutions | 21.20 % | ||||
| Number Of Shares Shorted | 90.95 K | ||||
| Price To Book | 0.14 X | ||||
| EBITDA | (19.85 M) | ||||
| Net Income | (18.35 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Theriva Stock Analysis
When running Theriva Biologics' price analysis, check to measure Theriva Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theriva Biologics is operating at the current time. Most of Theriva Biologics' value examination focuses on studying past and present price action to predict the probability of Theriva Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theriva Biologics' price. Additionally, you may evaluate how the addition of Theriva Biologics to your portfolios can decrease your overall portfolio volatility.